Kernal Biologics has technology that enables the delivery of messenger RNA therapies to a wider range of destinations in the body. The Series A financing comes as the startup works to advance its lead immuno-oncology program toward its first clinical test.
Currently, according to Tufts researchers, clinical trials in a variety of therapeutic areas experience patient dropout rates close to 20%, with the consent process being the number 1 factor contributing to this figure.
It is critical that the consent process be tailored to ensure that participants understand what's being asked of them and how their data will help further future disease treatment. The Solution: eConsent
Click hereto learn how to optimise eConsent for maximum patient centricity.
Don't miss out on this valuable opportunity to meet and discuss the latest trends and opportunities. Don't miss your chance to save with the Super Early Bird Rate.
The rising levels of both type 1 and type 2 diabetes in American youth is quickly becoming a major public health concern. To help address this problem, Mount Sinai partnered with mPulse Mobile, a company that offers a AI-based mobile patient messaging platform. Together with a group of teenage community members, they created a text message-based youth diabetes prevention program focused on integrating healthy behaviors into teens' lives.
The Supreme Court's majority opinion in Dobbs will create a big mess around what data will be revealed and the repercussions that will come when data are obtained. Individuals will bear the brunt of the burden while it all gets figured out.
Exo recently partnered with Henry Ford Health to validate its software platform for point-of-care ultrasounds. The health system's physicians will work with the company to increase the platform's ease of use, as well as commercialize the mobile ultrasound device Exo is developing.
Seniors' demand for Medicare Advantage plans shows no signs of slowing down any time soon, and that means CMS is likely to continue accelerating its FWA audits of MA plans, particularly given the prevalence of Covid-19-related fraud.
Two years after the stinging FDA rejection of its drug for the fatty liver disease NASH, Intercept Pharmaceuticals has more safety and efficacy data from a pivotal study that could support resubmission of a new drug application. The biotech said it will meet with the FDA later this month.
Replace the tedious manual resume screening process! Learn how AI frameworks and technology are streamlining the recruiter/candidate experience, resulting in healthcare industries hiring skilled and knowledgeable personnel quickly and effectively.
No comments